SCHEMBL13009396

SCHEMBL13009396

c1ccc2c(c1)Sc1ccccc1N2c1ccc2c(-c3ccc4ccccc4c3)c3ccc(N4c5ccccc5Sc5ccccc54)cc3c(-c3ccc4ccccc4c3)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 8/20 0.41
SLC6A3 Q01959 2/20 0.39
HTR2C P28335 1/20 0.39
ADRA1A P35348 1/20 0.39
HTR2B P41595 1/20 0.39
HTR6 P50406 1/20 0.39
HDAC6 Q9UBN7 1/20 0.38
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSP90AA1 P07900 1/20 0.36
ACHE P22303 1/20 0.35
MAOA P21397 1/20 0.33
GSTP1 P09211 1/20 0.32
ESR1 P03372 1/20 0.32
ESR2 Q92731 1/20 0.32
CYP1A2 P05177 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
MET P08581 1/20 0.31
ALOX5 P09917 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13009124 1.00 BCHE (0.41) BCHESLC6A3HTR2CADRA1AHTR2B
SCHEMBL13427143 0.96 BCHE (0.39) BCHESLC6A3HTR2CADRA1AHTR2B
SCHEMBL13428265 0.96 BCHE (0.39) BCHESLC6A3HTR2CADRA1AHTR2B
SCHEMBL13427173 0.96 BCHE (0.39) BCHESLC6A3HTR2CADRA1AHTR2B
SCHEMBL13008267 0.95 BCHE (0.38) BCHESLC6A3HTR2CADRA1AHTR2B
SCHEMBL13427158 0.95 BCHE (0.38) BCHESLC6A3HTR2CADRA1AHTR2B
SCHEMBL13427178 0.95 BCHE (0.38) BCHESLC6A3HTR2CADRA1AHTR2B
SCHEMBL13008258 0.95 BCHE (0.38) BCHESLC6A3HTR2CADRA1AHTR2B
SCHEMBL13008256 0.95 BCHE (0.39) BCHESLC6A3HTR2CADRA1AHTR2B
SCHEMBL13427170 0.94 BCHE (0.38) BCHESLC6A3HTR2CADRA1AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2256176-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-12-01 EP disclosed
US-20100051106-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-03-04 US disclosed
US-20100051106-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same GRACEL DISPLAY INC. (KR) 2010-03-04 US disclosed
EP-2141214-A2 Novel organic electroluminescent compounds and organic electroluminescent device using the same Gracel Display Inc. (KR) 2010-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100051106-A1 Novel organic electroluminescent compounds and organic electroluminescent device using the same RPL36, RPL39, RPL36A BCHE 3337/4885SLC6A3 2644/4885HTR2C 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.